{"id":73993,"date":"2024-09-01T15:46:00","date_gmt":"2024-09-01T13:46:00","guid":{"rendered":"https:\/\/www.ipsen.com\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/"},"modified":"2025-08-21T09:06:48","modified_gmt":"2025-08-21T07:06:48","slug":"une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl","status":"publish","type":"lay_language","link":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/","title":{"rendered":"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d’un cancer du rein \u00e0 un stade avanc\u00e9 qui n’a pas pu \u00eatre trait\u00e9 par chirurgie et dont l’\u00e9tat s’est aggrav\u00e9 apr\u00e8s le traitement initial"},"content":{"rendered":"\n

Cabometyx\/Cometriq<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":11,"template":"","lay_language_category":[80958],"class_list":["post-73993","lay_language","type-lay_language","status-publish","has-post-thumbnail","hentry","entry"],"acf":[],"yoast_head":"\nUne \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial - Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-21T07:06:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"73\" \/>\n\t<meta property=\"og:image:height\" content=\"73\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\",\"name\":\"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial - Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png\",\"datePublished\":\"2024-09-01T13:46:00+00:00\",\"dateModified\":\"2025-08-21T07:06:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png\",\"width\":73,\"height\":73},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d’un cancer du rein \u00e0 un stade avanc\u00e9 qui n’a pas pu \u00eatre trait\u00e9 par chirurgie et dont l’\u00e9tat s’est aggrav\u00e9 apr\u00e8s le traitement initial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial - Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/","og_locale":"fr_FR","og_type":"article","og_title":"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial - Global","og_url":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/","og_site_name":"Global","article_modified_time":"2025-08-21T07:06:48+00:00","og_image":[{"width":73,"height":73,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/","url":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/","name":"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d'un cancer du rein \u00e0 un stade avanc\u00e9 qui n'a pas pu \u00eatre trait\u00e9 par chirurgie et dont l'\u00e9tat s'est aggrav\u00e9 apr\u00e8s le traitement initial - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png","datePublished":"2024-09-01T13:46:00+00:00","dateModified":"2025-08-21T07:06:48+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2024\/11\/72x72-Lay-Summaries-1.png","width":73,"height":73},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/une-etude-ouverte-sur-le-cabozantinib-comme-traitement-de-2e-intention-chez-des-sujets-atteints-dun-carcinome-renal-non-resecable-localement-avance-ou-metastatique-avec-une-composante-a-cellules-cl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Une \u00e9tude sur le cabozantinib chez des personnes atteintes d’un cancer du rein \u00e0 un stade avanc\u00e9 qui n’a pas pu \u00eatre trait\u00e9 par chirurgie et dont l’\u00e9tat s’est aggrav\u00e9 apr\u00e8s le traitement initial"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language\/73993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/lay_language"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/11"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language\/73993\/revisions"}],"predecessor-version":[{"id":75783,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language\/73993\/revisions\/75783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/71083"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=73993"}],"wp:term":[{"taxonomy":"lay_language_category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language_category?post=73993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}